MIF-1 (TFA)

MIF-1 TFA (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 TFA inhibits melanin formation. MIF-1 TFA blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 TFA accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB) [1][2][3].

Product Specifications

CAS Number

[35240-69-8]

Product Name Alternative

Pro-Leu-Gly-NH2 (TFA) ; Melanostatin (TFA)

UNSPSC

12352209

Hazard Statement

H302, H312, H332

Target

Dopamine Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mif-1-tfa.html

Purity

99.34

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(NCC(N)=O)[C@H](CC(C)C)NC([C@@H]1CCCN1)=O.OC(C(F)(F)F)=O

Molecular Formula

C15H25F3N4O5

Molecular Weight

398.38

Precautions

H302, H312, H332

References & Citations

[1]Bocheva A, et, al. Antiopioid properties of the TYR-MIF-1 family. Methods Find Exp Clin Pharmacol. 2004 Nov;26 (9) :673-7.|[2]Valentijn JA, et, al. Melanostatin (NPY) inhibited electrical activity in frog melanotrophs through modulation of K+, Na+ and Ca2+ currents. J Physiol. 1994 Mar 1;475 (2) :185-95.|[3]Saleh MI, et, al. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny. Peptides. 1989 Jan-Feb;10 (1) :35-9.